IFNAR1 Controls Progression to Cerebral Malaria in Children and CD8+ T Cell Brain Pathology in Plasmodium berghei-Infected Mice by Ball, E. A. et al.
of February 8, 2017.
This information is current as
Mice
Infected−Plasmodium bergheiPathology in 
 T Cell Brain+Malaria in Children and CD8
 Controls Progression to CerebralIFNAR1
Carlos Penha-Gonçalves
Costa, Lígia Antunes Gonçalves, António Coutinho and
Martins, Maria Jesus Trovoada, Carla Benchimol, João 











, 21 of which you can access for free at: cites 48 articlesThis article 
Subscriptions
http://jimmunol.org/subscriptions
 is online at: The Journal of ImmunologyInformation about subscribing to 
Permissions
http://www.aai.org/ji/copyright.html
Submit copyright permission requests at: 
Email Alerts
http://jimmunol.org/cgi/alerts/etoc
Receive free email-alerts when new articles cite this article. Sign up at: 
Print ISSN: 0022-1767 Online ISSN: 1550-6606. 
Immunologists, Inc. All rights reserved.
Copyright © 2013 by The American Association of
9650 Rockville Pike, Bethesda, MD 20814-3994.
The American Association of Immunologists, Inc.,
 is published twice each month byThe Journal of Immunology






















































The Journal of Immunology
IFNAR1 Controls Progression to Cerebral Malaria in
Children and CD8+ T Cell Brain Pathology in Plasmodium
berghei–Infected Mice
Elizabeth Ann Ball,* Maria Rosa´rio Sambo,*,†,‡ Madalena Martins,*,x
Maria Jesus Trovoada,*,{ Carla Benchimol,‡ Joa˜o Costa,* Lı´gia Antunes Gonc¸alves,*
Anto´nio Coutinho,* and Carlos Penha-Gonc¸alves*
Development of cerebral malaria (CM), a severe and fatal form of clinical Plasmodium falciparum infection, results from
a damaging cascade of vascular, inflammatory, and immunological host responses that leads to brain injury. Progression to
CM can be modified by host genetic factors. Our case-control study in Angolan children aimed at highlighting the role of IFN (a,
b) receptor 1 (IFNAR1) in progression to CM. We report a robust association between IFNAR1 and CM protection, as well as
detailed studies showing analogous protection from experimental CM in Ifnar12/2 mice infected with P. berghei ANKA. We
developed a novel cell-transfer protocol that enables spleen cell priming in the absence of disease. This led to the discovery that
IFNAR1 expression in CD8+ T cells is crucial and can abrogate resistance to experimental CM in Ifnar12/2 mice. Splenic CD8+
T cells from Ifnar12/2 mice are functionally activated upon infection, yet are unable to mediate experimental CM development
within the brain tissue. Our findings prove that IFNAR1 signaling unleashes CD8+ T cell effector capacity, which is vital for
CM, and raises the hypothesis that the cohesive role of IFNAR1 in both human and mouse CM operates through CD8+ T cell
triggering. The Journal of Immunology, 2013, 190: 5118–5127.
C
erebral malaria (CM) is a severe, and often fatal, com-
plicated form of Plasmodium falciparum malaria, af-
fecting mostly children in endemic regions (1–3). Although
adhesion and sequestration of infected RBCs (iRBCs) in brain
microvasculature leads to blood vessel occlusion and is central to
CM pathogenesis (4), immunological mechanisms operating dur-
ing the development of CM remain unclear.
Accessibility to human tissues limits research into understanding
the progression and control of CM development in humans (5).
Therefore, use of the mouse model, termed “experimental CM”
(ECM), has enabled researchers to uncover cellular and molecular
components occurring in CM. Recent articles addressed the rele-
vance of the mouse model of ECM and emphasized the need for
identifying consistent factors between the mouse model and hu-
man studies (6–9). Because such factors are seldom confirmed,
confounding lists of players in CM development have emerged.
However, one factor remaining implicit are CD8+ T cells (10, 11),
although the exact mechanisms that drive their pathogenesis in
CM remain unclear. Additionally, the role of cytokines in human
CM development was brought to light in recent genetic studies
(reviewed in Ref. 12). Initial studies by Hill and coworkers (13,
14) began exploring the necessary role of type I IFN (type I IFN)
in CM progression and found that genetic variants in IFNAR1 led
to protection from CM development. Because IFNAR1 is the key
signaling receptor mediating type I IFN activity (15) and is
expressed on virtually every cell surface (16, 17), the impact that
type I IFN has on the immune response is vast. In particular, type I
IFN was shown to be involved in the priming of CD8+ T cells (18,
19) and in the generation of a robust immune response to infection
(20, 21). Recent studies addressed the actions of type I IFN,
through the IFNAR1 receptor, in response to hemozoin derivatives
(22), as well as in controlling parasite burden upon Plasmodium
infection (23). However, the exact caliber of IFNAR1 action in
CM development remains unexplored.
We performed a genetic study to analyze IFNAR1 involvement
in the progression of CM versus uncomplicated malaria (UM). We
selected children, the primary risk group of severe malaria, from
an area of Angola where malaria transmission is perennial (24).
We report in this article that variants of IFNAR1 strongly associate
with CM protection, which drove the use of Ifnar12/2 mice to
interrogate the action of IFNAR1 in CM pathogenesis. We de-
scribe ECM protection in Ifnar12/2 mice and, through design of
a novel cell-transfer protocol, we expose the necessity of IFNAR1
expression in CD8+ T cells during the development of ECM.
Materials and Methods
Patient and control samples
A total of 272 children, living in Luanda and ranging from 6 mo to 13 y
of age, were enrolled in the current study. Ethical permission for this study
was granted by the Ethical Committee of the Hospital Pedia´trico David
Bernardino in Luanda, appointed by the Angolan Ministry of Health.
Written, informed consent was obtained from the parents or guardians of
each child. Subjects were selected from patients at Hospital Pedia´trico
David Bernardino. The details of the data set were described previously
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(25). Briefly, samples were collected from children aged 6–156 mo,
between February 2005 and May 2007, and included 130 patients with
CM and 142 patients with UM. Malaria was diagnosed on the basis of
a positive asexual parasitemia detected on a Giemsa-stained thick smear
(26). CM was defined according to the World Health Organization cri-
teria: a coma score , 3 on the Blantyre Scale for children ,60 mo or
a coma score , 7 on the Glasgow Scale for children $60 mo. Meningitis
and encephalitis were ruled out by cerebrospinal fluid analysis after
lumbar puncture. Exclusion criteria were different known etiologies of
encephalopathy and hypoglycemia (glycemia , 40 mg/dl). Patients with
consciousness disturbances or with other diseases were also excluded
from this group. The UM group represents patients with malaria diagnosis
and febrile illness without any clinical finding suggestive of other causes
of infection and with no manifestations of severe malaria.
Genotyping
Genomic DNA was extracted from whole blood using the Chemagen
Magnetic Bead technology. DNA preparations were quantified using
PicoGreen reagents, according to the supplier’s instructions. Twenty-seven
single nucleotide polymorphisms (SNPs) covering the IFNAR1 region
were initially genotyped using the Sequenom’s iPlex assay (San Diego,
CA) and the Sequenom MassArray K2 platform by the Genomics Unit of
the Instituto Gulbenkian de Cieˆncia.
Extensive quality control was performed using eight HapMap (http://
hapmap.ncbi.nlm.nih.gov/) controls of diverse ethnicity, Hardy–Weinberg
equilibrium with p . 0.01, and a minimum 90% call rate for each SNP.
Genotype determinations were performed blinded to affection status. Only
SNPs with minor allele frequency . 1% in both groups were analyzed for
association. Nine SNPs in IFNAR1 (rs224359, rs2252930, rs12626750,
rs2834197, rs2226300, rs2254315, rs1012943, 2843996, and 2254305) did
not meet the quality control criteria and were excluded. Samples with
,75% call rate and duplicates were excluded from analysis; a total of 33
samples was excluded. The final data set used in the analysis consisted of
239 children: 110 CM patients (mean age, 54.6 mo) and 129 UM patients
(mean age, 49.1 mo).
Association testing
The x2 tests for Hardy–Weinberg equilibrium in both groups, allelic and
haplotypic association of SNPs with progression to CM, and linkage dis-
equilibrium plots were performed using Haploview 4.2 (27). A diagram
with representation of the allelic genetic-association results was produced
by the snp.plotter R package (28). Association analyses were performed
with logistic regression and adjusted for potential confounding effects of
age using the SNPassoc v.1.4-9 package (29) implemented in R freeware
(http://cran.r-project.org/). Results were considered suggestive below the
conventional probability level of 0.05. Bonferroni corrections for multiple
tests were carried out to exclude type I errors (the significance level for 18
tests is set at p value , 2.78 E23).
Animals
Male, 8–12-wk-old C57BL/6, B6.Ly5.1, Ifnar12/2, and BALB/c mice
were bred and used as provided by the Instituto Gulbenkian de Cieˆncia in-
house animal facility. Ifnar12/2 mice (Ifnar1-tm-Agt) (30) were originally
a gift to the institute from Michel Aquet, Institute of Molecular Biology,
University of Zurich, Switzerland. Ifnar12/2 mice were backcrossed onto
the C57BL/6 background (98.7–99.36% C57BL/6 background outside of
the congenic region, as confirmed by the animal facility at Instituto Gul-
benkian de Cieˆncia). All procedures were in accordance with national
regulations on animal experimentation and welfare, as approved by the
Instituto Gulbenkian de Cieˆncia Ethics Committee.
Parasite, infection, and ECM disease assessment
All infections used 1 3 106 Plasmodium berghei ANKA-GFP (PbA)-par-
asitized iRBCs (31) given via i.p injection. Frozen iRBC stocks were ex-
panded in C57BL/6 mice prior to infection. Parasitemia was determined as
the percentage of GFP+ RBCs, using flow cytometry analysis (FACScan
Cell Analyzer; Becton Dickinson) and noninfected RBCs as negative
control. ECM development was monitored from day 5 postinfection (PI),
including head deviations, paralysis, ataxia, and convulsions (32). ECM-
susceptible mice developed symptoms at days 6–7 PI and died within 4–5 h.
Mice resistant to ECM died around days 22–25 from anemia and hyper-
parasitemia without displaying neurologic symptoms.
Blood–brain barrier integrity
Upon display of ECM-induced coma in C57BL/6 mice, the experimental
groups of mice were injected with 100 ml 2% Evan’s blue dye (Sigma),
sacrificed 1 h postinjection, and perfused intracardially with 15 ml ice-cold
PBS. Brains were dissected, weighed, and immersed in 2 ml formamide
(Merck), covered at 37˚C for 48 h, to allow extraction of Evan’s blue dye;
images were taken after the 48 h period. Noninfected mice from each
group were used as controls. Absorbance of dye was measured at 620 and
740 nm using spectrophotometry (Thermo Spectronic Helios Delta). Using
a standard curve, data were calculated and expressed as mg Evans blue
dye/mg brain tissue.
Histology
Infected C57BL/6 and Ifnar12/2 mice were sacrificed upon observation of
clinical signs of ECM in C57BL/6 mice, ∼day 6 PI. Noninfected C57BL/6
and Ifnar12/2 mice were used as controls and sacrificed at the same time
point. For H&E staining, brains were carefully removed, fixed in 10%
neutral-buffered formalin, embedded, sectioned (4 mm), mounted with
Entellan (Merck, Darmstadt, Germany), and stained with H&E, following
standard procedures. CM and brain pathology were assessed by routine
histopathology in coronal brain sections of the same anatomical location.
Bright-field images were captured using a Leica DMD108 microscope
(Leica Microsystems); 103 (numerical aperture: 0.40) and 403 (numer-
ical aperture: 0.95) objectives were used. Adobe Photoshop software
(Adobe) was used to compose images and adjust the contrast.
Gene expression
Infected C57BL/6 and Ifnar12/2 mice were sacrificed at days 5–7 PI.
Ifnar12/2micewere also sacrificed at days 9 and 11 PI; C57BL/6micewere
not collected at these time points due to death from ECM. Noninfected
C57BL/6 and Ifnar12/2 mice were used as controls and represent day 0.
Brains were dissected, fast frozen in liquid nitrogen, and stored at 280˚C.
Brains were then homogenized, and a final brain weight of 20 mg was used for
total RNA extraction (RNeasy Mini Kit; QIAGEN). RNA quality was deter-
mined using Nanodrop, and a final elution of 50 ml was extracted. One mi-
crogram of total RNA was converted to cDNA (Transcriptor High Fidelity
cDNA Synthesis Kit; Roche) using random hexamer primers, and a final
volume of 10 ml the cDNA reaction was diluted 1:3 in RNase-free water to be
used for mRNA quantification. Tnf-a and Il-10 mRNA was quantified using
TaqMan Gene Expression Assays from ABI (Mm00443258_m1 and
Mm99999062_m1, respectively).P. berghei ANKA rRNAwas quantified using
specific primer sequences: forward 59-CCG ATA ACG AAC GAG ATC TTA
ACC T-39, reverse 59-CGT CAA AAC CAATCT CCC AATAAAGG-39 and
probe 59-ACT CGC CGC TAA TTA G-39 (FAM/MGB), all with TaqMan
Universal PCR Master Mix. T lymphocyte (Cd3e) expression was quantified
using a specific primer sequence, forward 59-TCT CGG AAG TCG AGG
ACAGT-39 and reverse 59-ATCAGCAAGCCCAGAGTGAT-39 (33), using
Power SYBR Green PCR Master Mix (Applied Biosystems). Gene expres-
sion–quantification reactions were performed on an ABI Prism 7900HT sys-
tem, according to the manufacturer’s instructions; a total volume of 10ml PCR
reactions was amplified for 45 cycles. Relative quantification of specific
mRNAwas normalized to the mouse housekeeping geneACTB (Mouse ACTB
Endogenous Controls; ABI), used in multiplex PCR with the target genes and
calculated using the DDCt method.
Presensitization protocol
For infected blood donor mice, blood was collected by mandibular vein
puncture into an Eppendorf tube containing 10 ml heparin (Heparina Leo;
LEO Pharmaceutical Products) from infected mouse at day 6 PI, upon
display of ECM symptoms and when parasitemia was ∼30%. Parasitemia
was measured to calculate injection of 4 3 106 iRBCs into cell donor
mice. Collected blood was then placed on ice in a 50-ml Falcon tube and
irradiated at 20,000 rad (Gammacell 2000; Mølsgaard Medical). Irradiated
iRBCs were then resuspended in PBS and injected i.p. into cell donor
mice. At day 6 postirradiated iRBC injection, cell donor mice were sac-
rificed, and purified spleen cell populations were injected into recipient
mice; recipient mice were left noninfected or were infected with 1 3 106
PbA i.p. 1 h after transfer. Parasitemia and ECM development were
monitored from day 5 PI. For control noninfected blood donor mice, mice
were bled, and an equivalent volume of noninfected RBCs was irradiated
and diluted in PBS in the same manner as above.
Spleen cell transfers
Single-cell suspensions were prepared from spleens of cell donor mice. For
total spleen cell transfers, cells were washed twice in PBS, counted in
a hemocytometer, resuspended in PBS, and injected at 5 3 106/100 ml into
recipient mice. For spleen CD8+ cell transfers, cells were washed twice in
PBS, 2% FCS and incubated with anti-mouse CD8–Alexa Fluor 647 Ab
(clone YTS169; in-house production) for 30 min on ice. For CD8+Ly5.1/2+
cell transfers, cells were incubated with anti-mouse CD8–Alexa Fluor 647
Ab (clone YTS169; in-house production), anti-mouse CD45.1-FITC Ab
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(clone 820; BD Pharmingen), or anti-mouse CD45.2-PE Ab (clone 104.2;
in-house production) for 30 min on ice. Stained cells were washed in PBS,
2% FCS and sorted (FACSAria Multicolor Cell Sorter; Becton Dickinson)
by combining lymphocyte morphological gating and relevant Ab labels.
For CD8+ transfers, cells were collected as purified CD8+ cells and CD82
(depleted) groups of cells. For CD8+Ly5.1/2 transfers, cells were gated for
CD8+ cells, within which CD45.1+ or CD45.2+ populations were collected.
Purified cell populations were washed in PBS and counted. Cells were
injected i.v. at 3 3 106/100 ml into recipient mice. Respective groups of
recipient mice were then infected with 1 3 106 iRBCs/100 ml PbA 1 h
after cell transfer. Mice were monitored for parasitemia and ECM devel-
opment from day 5 PI.
Analysis of spleen cells
Single-cell suspensions were prepared from spleens of infected C57BL/6
and Ifnar12/2 mice at day 5 PI; noninfected mice from both groups were
used as control. Cells used for total cell counts and activation profile were
prepared as single-cell suspensions: from 5 ml total cells, 200 ml/sample
was plated in a 96-well round-bottom plate, and cells were centrifuged;
pelleted; resuspended in Fc Block for 20 min on ice; washed in PBS, 2%
FCS; and resuspended in either anti-mouse CD8–Alexa Fluor 647 Ab
(clone YTS169; in-house Ab) or CD4–Alexa Fluor 647 (clone GK 1.5; in-
house Ab) with CD44-FITC (clone IM7; BD Pharmingen 553133) and
CD62L-PE (clone Mel 14; eBioscience 12-0621-85) for 20 min on ice.
Cells were then washed, resuspended in 100 ml PBS, 2% FCS plus 20 ml
propidium iodide (1 mg/ml; P-4170; Sigma) and 10 ml 5 3 105 beads
(Beckman Coulter nominal 10 mm Latex Beads). For intracellular staining,
cells were washed and resuspended in RBC lysis buffer; washed and
resuspended in 100 ml RPMI 1640 medium supplemented with 10% FCS,
10 U/ml Pen-Strep, 1% sodium pyruvate, 1% HEPES 1 M, 1% L-gluta-
mine, and 0.01% 2-ME; centrifuged; and resuspended in 200 ml RPMI
1640 supplemented medium containing 10 mg/ml brefeldin A for fixation
of intracellular cytokine production and 100 ng/ml of PMA and 500 ng/ml
ionomycin used for cell stimulation. Cells were stimulated at 37˚C, 5%
CO2 for 4 h. Cells were then processed for extracellular staining; cells
were centrifuged, pelleted, resuspended in Fc Block for 20 min on ice,
washed in PBS, 2% FCS, and resuspended in anti-mouse CD8–Alexa Fluor
647 Ab (clone YTS169; in-house Ab) for 20 min on ice. Cells were then
washed and resuspended in 2% paraformaldehyde for fixation for 30 min at
room temperature (RT), washed twice in PBS, resuspended in 200 ml PBS,
2% FCS, and stored at 4˚C overnight. The following day, cells were pel-
leted and resuspended in permeabilization buffer (10% saponin in PBS, 2%
FCS) for 10 min at RT in preparation for intracellular staining. Cells were
then washed, pelleted, and incubated with anti-mouse granzyme B (GrB)–
FITC (clone NGZB; eBioscience) and anti-mouse IFN-g–PE (clone
XMG1.2; BD Pharmingen) for 30 min at RT. Cells were then washed twice
in permeabilization buffer and then twice in PBS, 2% FCS and resus-
pended in 150 ml PBS, 2% FCS plus 5 3 105 beads (as before). All cell
analyses were performed using a FACSCalibur cell analyzer and FlowJo
software (version 7). Single-staining preparations were used for control
compensation of double-staining analysis.
Analysis of brain-sequestered leukocytes
Infected C57BL/6 and Ifnar12/2 mice were sacrificed at day 6 PI and
perfused pericardially (as described above), and brains were placed in 10
ml HBSS supplemented with Collagenase VIII (0.2 mg/ml; Sigma). Brains
were then smashed and incubated for 30 min at 37˚C. Each sample was
passed through a 100-mm strainer and centrifuged for 10 min at 1500 rpm.
Supernatant was discarded, and samples were resuspended in 10 ml PBS
and centrifuged. Samples were resuspended in 10 ml 30% Percoll gradient
(Percoll; GE Healthcare, BioSciences) and centrifuged for 20 min at 2500
rpm at RT, without brake. The supernatant was aspirated carefully, and the
pellet was resuspended in 50 ml PBS and centrifuged. The supernatant
was discarded, and each sample pellet was resuspended to a final volume
of 200 ml. Cells were centrifuged and resuspended in 100 ml RBC lysis
buffer, incubated for 5 min at RT, washed twice in 200 ml PBS, 2% FCS,
resuspended in supplemented RPMI 1640 medium, and prepared for extra-
and intracellular staining and analysis, as described above.
Statistical analysis
The nonparametric Mann–Whitney U test was used for analysis when
comparing data from two groups of mice. One-way ANOVA was used to
compare three or more groups of data. Survival analysis was assessed by
FIGURE 1. IFNAR1 gene variants protect against
malaria progression to CM syndrome. Results of ge-
notypic association tests under the dominant model at
18 IFNAR1 SNPs, depicted at the bottom of the hori-
zontal axis according to relative physical distance. (A)
Scaled diagram of the IFNAR1 gene structure: exons
are marked with their corresponding number, 59 un-
translated region and 39 untranslated region are repre-
sented by gray boxes, and introns are represented by
black lines between exons. (B) Genotypic p values of
association tests were obtained by comparing 110 cases
of CM with 129 patients with UM using logistic re-
gression and adjusted for age. Thresholds for sugges-
tive association (p = 0.05) and for significant
association after multiple testing Bonferroni correction
(p = 2.78 E23) are represented. (C) Linkage disequi-
librium plot representing pairwise R2 in a gray scale
and revealing the two hap blocks in the analyzed re-
gion. This diagram is an adaptation of the figure pro-
duced by the snp.plotter R package and the linkage
disequilibrium map obtained from Haploview 4.2.
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the log-rank test. All tests were performed using Prism GraphPad 4. The p
values #0.05 were considered statistically significant.
Results
IFNAR1 variants are associated with protection against
clinical progression to CM
The IFNAR1 gene has been associated with severe forms of malaria
(13, 14). In this study, we used a cohort of Angolan children to
identify IFNAR1 genetic variants that specifically modify the risk for
progressing from uncomplicated forms of malaria to CM syndrome.
We compared genotype frequencies of SNPs in infected children that
developed CM (n = 110) versus children that presented with clinically
UM (n = 129). After age correction, 8 of 18 IFNAR1 SNPs showed
a suggestive association (p , 0.05) with progression to CM (Fig.
1B), possibly under a dominant mode of action (Supplemental
Table II). The two markers having the strongest association with
progression to CM, rs2856968 (p = 1.33E26) and rs2253923
(p = 5.77E25), remained significantly associated after conser-
vative Bonferroni correction for multiple testing (p , 2.78E23)
(Fig. 1B). Because the two SNPs are in strong linkage disequi-
librium (r2 = +0.77), this result suggests a single genetic effect in
CM protection (Fig. 1D).
Haplotypic-association analysis of eight SNPs in the 59 region of
IFNAR1 (encompassing upstream regulatory region intron 1 and
intron 2) identified one haplotype (hap) that shows robust asso-
ciation with CM protection (Phap = 6.89E27; ORhap = 0.34).
Conversely, the most frequent haplotype for the same eight SNPs
shows an increased risk for CM progression (Phap = 8.0E24;
ORhap = 1.87). Together, this genetic evidence strongly suggests
that specific minor frequency alleles of the IFNAR1 gene provide
protection against CM. This suggests a decisive role for IFNAR1
during the inflammatory response to malaria infection and, spe-
cifically, at dictating progression to CM.
Ifnar12/2 mice are protected from development of ECM and
brain pathology
We used the mouse model of ECM to ascertain whether IFNAR1 is
involved in inflammation evoked by malaria infection (6). In line
with a recent report (22), we observed that PbA infection in
Ifnar12/2 mice led to strong resistance to ECM (75% ECM re-
sistance, Fig. 2A) compared with susceptible C57BL/6 control
mice. Ifnar12/2 mice that resist ECM development die between
days 25 and 30 from anemia and hyperparasitemia and showed
parasitemia comparable to C57BL/6 mice up to day 6 PI (Fig. 2B).
This indicated that ECM resistance in Ifnar12/2 mice was not
related to decreased peripheral parasite burden.
Disruption of the blood–brain barrier (BBB) is a hallmark of
ECM pathology (34). We analyzed infected and noninfected
C57BL/6, Ifnar12/2, and ECM-resistant BALB/c mice for barrier
compromise using Evans blue. Like BALB/c mice, Ifnar12/2
mice displayed no BBB compromise (Fig. 3A, 3B), as opposed to
C57BL/6 mice, which showed abundant dye leakage in the brain.
Histopathological analysis of infected C57BL/6 brain sections
exhibited prominent mononuclear cell accumulations within brain
microvessels (Fig. 3D), evidence of disruption of vessel walls and
endothelial cell destruction (Fig. 3E), and parenchymal hemor-
rhagic lesions containing iRBCs (Fig. 3F). In contrast, ECM-
resistant Ifnar12/2 mice displayed mild intravascular accumula-
tion of mononuclear cells (Fig. 3H), intact endothelial cells (Fig.
3I), and absence of hemorrhagic lesions with iRBCs seen within
the lumen of blood vessels only (Fig. 3J). These results show that,
despite abnormal mononuclear accumulation within brain micro-
vessels and the presence of intraluminal iRBCs, infected Ifnar12/2
mice do not exhibit pathology typical of ECM.
Ifnar12/2 mice display a delayed brain inflammatory response
upon infection
To further investigate the mechanisms underlying ECM protection
in Ifnar12/2 mice, we evaluated cytokine production and parasite
burden within the brain tissue of infected C57BL/6 and Ifnar12/2
mice. Comparison of P. berghei rRNA quantification showed no
significant differences during the early time course of infection,
strongly suggesting that ECM protection in Ifnar12/2mice was not
attributable to reduced brain parasite burden (Fig. 4A). We also
observed that kinetics of Cd3 mRNA expression in the brain
leading up to ECM manifestations were slightly lower in Ifnar12/2
mice but not significantly different from C57BL/6 mice; this
suggests that T cell migration to the brain during infection was not
impaired in Ifnar12/2 mice (Fig. 4B). Nevertheless, we found that,
in the brain of Ifnar12/2 mice, the expression of inflammatory
markers (i.e., Tnf and Il10) had lower induction in the period
preceding ECM onset and showed delayed kinetics compared with
infected C57BL/6 mice. Overall, these results indicate that, despite
the accumulation of iRBCs and the presence of T cells, Ifnar12/2
mice show a diminished exacerbation in their inflammatory
responses, deterring the development of brain pathology within
the time frame of ECM development.
Presensitization for cell transfer
We questioned in which cell type IFNAR1 was fundamental to
cause ECM development in mice. To this end, we developed a novel
cell-transfer protocol to determine the ability of individual cell
types to restore ECM susceptibility in Ifnar12/2 mice (Fig. 5A).
Donor mice were exposed to irradiated iRBCs, allowing relevant
blood-stage parasite Ags to prime in vivo immune system cells
that were then used in transfer experiments. The irradiated parasite
is unable to reinvade RBCs; therefore, (exposed) donor mice do
not develop parasitemia or ECM. We analyzed the T cell profiles
FIGURE 2. Ifnar12/2 mice are protected from ECM and show no de-
crease in parasite burden. C57BL/6 and Ifnar12/2 mice were infected with
1 3 106 PbA-infected RBCs via i.p. injection. (A) Survival curve (n = 17),
log-rank test. Time window of C57BL/6 ECM development is shaded. (B)
Parasitemia progression (n = 17). Data were collected from at least four
independent experiments. **p = 0.0016 (day 6 PI), **p = 0.0021 (day 7
PI), unpaired, two-tailed t test.
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of C57BL/6 mice that received iRBCs, as well as mice that re-
ceived irradiated iRBCs (Fig. 5B, 5C). We found that the numbers
of CD8+ T cells in mice that received irradiated iRBCs were not
as high as those found in infected C57BL/6 mice but were similar
in number to activated CD8+ T cells (CD44hi and CD62Llow)
(Fig. 5B). We noted that CD4+ T cell numbers and activation
profile were not significantly different between mice that received
irradiated iRBCs or iRBCs (Fig. 5C). Together, this suggests that
irradiated iRBCs induce activation of both CD8+ and CD4+
T cells. A group of C57BL/6 cell donor mice was injected with
irradiated iRBCs and then infected with 1 3 106 nonirradiated
PbA iRBCs 7 d later (as per normal infection); all mice developed
ECM and died by day 7 PI (data not shown). We concluded that
our protocol does not confer protective immunity but rather is
a protocol of immune cell presensitization that occurs in the ab-
sence of parasite expansion or disease development. We anticipate
that this method will be useful in investigating pathogenic
mechanisms of malaria blood-stage infection in future mouse
models.
C57BL/6 spleen cells confer ECM susceptibility to Ifnar12/2
mice
Total splenocytes were transferred from C57BL/6 mice that had
received irradiated iRBCs (cell donors) to Ifnar12/2 mice. Upon
infection, recipient Ifnar12/2 mice showed 75% development of
ECM, 6–12 d PI, within the ECM time frame of susceptible
C57BL/6 mice (Fig. 5D). This demonstrates that C57BL/6
splenocytes presensitized to irradiated iRBCs are effective at
restoring ECM susceptibility in Ifnar12/2 mice. In a control ex-
periment, total splenocytes were transferred from C57BL/6 donor
mice that had received noninfected irradiated RBCs to Ifnar12/2
mice. When infected 1 h posttransfer, recipient mice developed
FIGURE 3. Ifnar12/2 mice are protected from BBB compromise and show reduced mononuclear cell accumulation in brain microvasculature. C57BL/6,
Ifnar12/2, and BALB/c micewere infected with 13 106 PbA iRBCs i.p. and analyzed at day 6 PI. (A) BBB integrity was assessed in all infected groups of mice
by Evan’s Blue perfusion. Noninfected mice from each group were used as controls (n = 3–5 mice/group). Images are representative of two independent
experiments. (B) Quantification of Evan’s Blue dye was measured as micrograms of dye per milligram of brain tissue (n = 3–4 mice/group). ***p # 0.001,
ANOVA, Tukey multiple-comparison test. Data are representative of two independent experiments. (C–J) H&E staining of brain sections from C57BL/6 and
Ifnar12/2 mice (noninfected mice were used as controls). Mice were sacrificed upon display of ECM in C57BL/6 mice. Coronal sections of brain microvas-
culature and mononuclear cell accumulation in noninfected C57BL/6 mice (C), infected C57BL/6 mice (D–F), noninfected Ifnar12/2 mice (G), and infected
Ifnar12/2 mice (H–J). Original magnification in (C), (D), (G), and (H) 3400 and in (F) and (J) 31000; scale bars, 30 mm. Detail images of coronal sections of
infected C57BL/6 mice showing absence of endothelial cells (E, arrows) and presence of hemorrhagic foci with iRBCs (F, arrowhead). Sections of infected
Ifnar12/2mice showing intact endothelial cells (J, arrow) and intraluminal iRBCs (I, J, arrowhead). Images are representative of three mice examined per group.
FIGURE 4. Parasite accumulation and brain-inflammation markers in
infected Ifnar12/2 mice. C57BL/6 (black bars) and Ifnar12/2 (white bars)
mice were infected with 1 3 106 PbA iRBCs i.p., and brain RNA was
extracted at the indicated time points for RT-PCR quantification. (A) P.
berghei rRNA relative quantification; day 5–infected C57BL/6 mice were
used as a calibrator. Expression of Cd3 (B), Tnf-a (C) and Il-10 (D);
noninfected C57BL/6 mice were used as a calibrator, represented as day
0 (n = 3–4 mice/group/d). Data are mean 6 SD from one of two inde-
pendent experiments. Time window of C57BL/6 ECM onset is shaded.
Nonparametric Mann–Whitney U test.
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FIGURE 5. Ifnar12/2 mice succumb to ECM upon cell transfer of parasite-sensitized splenocytes, explicitly CD8+ cells. (A) Schematic representation of
presensitization protocol described in Materials and Methods. Total number and activation profile of splenic CD8+ (B) and CD4+ (C) T cells from C57BL/6
mice at 5 d postchallenge: noninfected (NI; black bar), infected with 13 106 PbA i.p. (gray bar), or injected with 43 106 irradiated iRBCs i.p. (striped bar)
(n = 4–6 mice/group). *p # 0.05, **p # 0.01, nonparametric Mann–Whitney U test. (D) Parasitemia (left panel) and survival (right panel) curves of
Ifnar12/2 mice that received total spleen cells from C57BL/6 pre-exposed donor mice; recipients were infected after transfer (N) or left noninfected (n).
Parasitemia (left panels) and survival (right panels) curves of Ifnar12/2mice that received sorted presensitized CD8+ spleen cells (N) or sorted presensitized
CD8- depleted spleen cells (s) from C57BL/6 pre-exposed cell donor mice (E) or Ifnar12/2 pre-exposed cell donor mice (F). Transfer control represents
infected Ifnar12/2 mice that received no cells ()) (n = 4–6 mice/group). Parasitemia: unpaired t test. Survival: log-rank test significant p values, n versus N
(in [D]) and N versuss (in [E]). All significant differences are displayed. Each plot represents one of at least two independent experiments. Time window of
ECM is shaded in survival plots. (G) Measurement of BBB compromise by Evans Blue perfusion in recipient Ifnarl2/2mice, as in (E) (n = 3–4 mice/group).
(H) Quantification of Evans Blue (EB) dye (n = 3–4 mice/group). Data in (G) and (H) represent one of two independent experiments. *p # 0.05, **p #
0.01, ***p # 0.001, ANOVA, Tukey multiple-comparison test.
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parasitemia like Ifnar12/2 mice that received infection only (no
cell transfer). Neither group of mice developed ECM, with all
mice dying around day 25 PI from anemia and hyperparasitemia
(Supplemental Fig. 1). This shows that C57BL/6 splenocytes ex-
posed to noninfected irradiated RBCs are unable to induce ECM
susceptibility in Ifnar12/2mice, indicating that RBC irradiation per
se has no impact on ECM development in recipient mice. We then
determined whether CD8+ spleen cells induced ECM in Ifnar12/2
mice. Sorted CD8+ or CD82 depleted cells, isolated from donor
C57BL/6 mice that received irradiated iRBCs, were transferred into
Ifnar12/2 mice (Fig. 5E). Recipient mice were then infected 1 h
after cell transfer. Parasitemia did not differ between the two groups
of mice compared with Ifnar12/2 mice that received infection only
(and no cell transfer). In contrast, we found ECM development only
in the group of Ifnar12/2 mice that received purified CD8+ cells.
This result indicates that transfer of presensitized C57BL/6 CD8+
cells is sufficient to restore susceptibility to ECM in Ifnar12/2mice.
Upon transfer of presensitized Ifnar12/2 CD8+ T cells to Ifnar12/2
mice, we found that recipient mice did not develop ECM; this led us
to conclude that only CD8+ IFNAR1+ cells from exposed C57BL/6
mice were able to cause ECM (Fig. 5F). By assessing BBB in-
tegrity, we confirmed the ability of presensitized CD8+ cells iso-
lated from C57BL/6 mice to induce bone fide ECM. We observed
BBB compromise only in Ifnar12/2 mice that received C57BL/6
CD8+ cells and not in CD8- cell–depleted recipient mice (Fig. 5G,
5H). Together, these results show that IFNAR1 is critical for CD8+
cell–mediated abrogation of ECM resistance in Ifnar12/2 mice.
Intrinsic CD8+ T cell properties trigger ECM development
We modified our cell-transfer protocol to ascertain whether ECM
induction was dependent on IFNAR1 expression in CD8+ cells (Fig.
6A). CD8+ cells were sorted from noninfected Ifnar12/2.Ly5.2
mice and transferred to previously nonlethally irradiated C57BL/6.
Ly5.1 mice, allowing for the discrimination of endogenous and
transferred CD8+ populations. Ly5.1/5.2 chimeric mice then re-
ceived irradiated iRBCs from a B6.Ly5.1 mouse. Seven days later,
Ly5.1 CD8+ and Ly5.2 CD8+ cell populations were sorted (Fig. 6B)
and transferred to Ifnar12/2 recipient mice. No differences in par-
asitemia progression were observed in either group compared with
Ifnar12/2 mice that received no cell transfer and infection only
(Fig. 6C). We found that only recipient Ifnar12/2 mice that had
received Ly5.1 IFNAR1+ CD8+ cells developed ECM, showing
100% disease incidence, whereas recipients of Ly5.2 IFNAR12
CD8+ cells maintained ECM resistance comparable to Ifnar12/2
mice that received no cell transfer and infection only. This strongly
suggests that deficiency in IFNAR1 signaling in CD8+ cells impairs
their ability to induce ECM in Ifnar12/2mice during PbA infection.
Ifnar12/2 mice display differing activation states in spleen and
brain tissue compared with C57BL/6 mice
To investigate CD8+ T cell impairments in Ifnar12/2 mice during
PbA infection, we analyzed the activation and expansion of CD8+
T cells in the spleen at day 5 PI, prior to ECM onset. We found
a significant difference between noninfected C57BL/6 and
Ifnar12/2 mice that was attenuated upon infection. This indicates
that infection-driven CD8+ T cell expansion was not impaired in
Ifnar12/2 mice (Fig. 7A). Similarly, splenic CD8+ T cells from
Ifnar12/2 mice do not show impairments in GrB or IFN-g ex-
pression upon infection (Fig. 7B, 7C). We also note that CD4+
T cell expansion and activation, as measured by IFN-g, are not
hindered in Ifnar12/2 mice upon infection compared with C57BL/6
mice (Supplemental Fig. 2).
FIGURE 6. Intrinsic Ifnar12/2 CD8+ cell im-
pairment protects from ECM. (A) Schematic rep-
resentation of experimental protocol. Noninfected
Ifnar12/2 mice were used as donors of 5 3 106
CD8+Ly5.2+ spleen cells that were transferred to
previously nonlethally irradiated B6.Ly5.1 recipient
mice. Six days posttransfer, Ly5.1/Ly5.2 chimeric
mice received 4 3 106 irradiated iRBCs from
a previously infected B6.Ly5.1 mouse. (B) Seven
days after iRBC infection, CD8+Ly5.2+ and CD8+
Ly5.1+ spleen cells were FACS sorted, as described
in Materials and Methods. The sorted CD8+ cell
populations were injected back into Ifnar12/2
recipients, and mice were infected with 1 3 106
iRBCs 1 h after cell transfer. (C) Parasitemia (left
panel) and survival (right panel) curves of Ifnar12/2
recipient mice that received either CD8+Ly5.1+ (n)
or CD8+Ly5.2+ cells (N) from pre-exposed chimeras
or no cell transfer and infection only as control ())
(n = 3–12 mice/group). Data are pooled from three
independent experiments. Time window of C57BL/6
ECM symptoms is shaded in survival plot. Para-
sitemia: unpaired t test between CD8+Ly5.1+ and
CD8+Ly5.2+ recipient groups (*p # 0.05). Survival:
*p # 0.05, log-rank test, n versus N.
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Likewise, we analyzed profiles of CD8+ T cells from the brain
of infected C57BL/6 and Ifnar12/2 mice at day 6 PI, upon
display of end-stage ECM symptoms in control C57BL/6 mice.
We found that the total number of CD8+ T cells sequestered in
the brain of Ifnar12/2 mice was significantly reduced compared
with C57BL/6 mice (Fig. 7D). Nevertheless, the vast majority of
brain-sequestered CD8+ T cells in both Ifnar12/2 and C57BL/6
mice were activated and showed a cytotoxic profile (Fig. 7E, 7F).
This indicates no faltering in sequestered Ifnar12/2 CD8+
T cells to exhibit a cytotoxic profile, as supported by mean
fluorescence intensity analysis of GrB and IFN-g in CD8+ T
cells upon infection compared with C57BL/6 mice (Supple-
mental Fig. 3).
We confirmed these results by analyzing sequestered CD8+
T cells on day 6 PI from Ifnar12/2 mice that received either CD8+
T cells (and were restored with ECM susceptibility) or CD82
depleted cells. As expected, higher numbers of CD8+ T cells, as
well as GrB+ and IFN-g+ CD8+ T cells, were seen in the brain of
mice that received CD8+ T cell transfer (Fig. 7G–I). However,
these results were not significantly different, suggesting that in-
duction of ECM in Ifnar12/2 mice is not strictly dependent on
accumulation of effector IFNAR1+ CD8+ T cells. Together, these
results suggest that ECM resistance in Ifnar12/2 mice operates
through impaired IFNAR1 signaling in CD8+ T cells.
Discussion
This work strengthens the role of type I IFNs/IFNAR1 signaling
in human cerebral malaria and uncovers the actions of IFNAR1
in ECM development. We found that IFNAR1 genetic variants
showed protection against progression to CM in a population of
Angolan children. In Gambian children, two SNPs, which were
identified in the IFNAR1 gene in intron 3 and exon 4, were as-
sociated with severe malaria and CM (13). However, the study of
Gambian, Kenyan, and Vietnamese populations (14) highlighted
positive associations in the 59 region of the IFNAR1 locus. This
was also found as a region of strong association in our study,
suggesting that the 59 region of the IFNAR1 gene known to control
transcriptional activity (35) represents a malaria-susceptibility
factor throughout diverse populations. Furthermore, the design
established in our study proved to be advantageous, allowing us to
evaluate specifically the association of IFNAR1 with disease
progression from UM to CM. IFNAR1 has also been associated
with AIDS progression (15) and clinical presentation of hepatitis
B virus infection (36), which allows the inference that IFNAR1
variants can affect type I IFN responses and govern the course and
progression of infectious diseases.
These results motivated the use of Ifnar12/2 mice to address the
mechanisms underlying the pathogenesis of CM in the ECM
mouse model. We found that protection from ECM in Ifnar12/2
FIGURE 7. IFNAR12 CD8+ T cells show activation
upon infection but not accumulation in the brain.
Numbers of CD8+ T cells (A, D), GrB+ CD8+ T cells
(B, E), and IFN-g+ CD8+ T cells (C, F) of infected and
noninfected C57BL/6 and Ifnar12/2 mice in the spleen
(A–C) and perfused brains (D–F). Numbers of CD8+
T cells (G), GrB+ CD8+ T cells (H), and IFN-g+ CD8+
T cells (I) in perfused brains of Ifnar12/2 recipient
mice that received sorted CD8+ or CD82 depleted
spleen cells from pre-exposed C57BL/6 donor mice.
Mice were analyzed for CD8+ T cells in the spleen on
day 5 PI and in the brain on day 6 PI when C57BL/6 or
Ifnar12/2 ECM-induced mice displayed symptoms of
ECM development (n = 3–5 mice/group). Data are
representative of three (A–F) or two (G–I) independent
experiments. [(B), C57BL/6 noninfected group mean:
2.8 3 105; Ifnar12/2 noninfected group mean: 8.0 3
104]. *p # 0.05, **p # 0.01, nonparametric Mann–
Whitney U test; all statistically significant differences
are shown.
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mice was not controlled via a reduction in parasite burden. Con-
flicting results have been found; one study (22) showed no de-
crease in parasitemia when using PbA infection in Ifnar12/2 mice,
whereas another study (23) reported a decrease in parasite burden
upon PbA-GFP + luciferase infection. It remains to be determined
whether different strains of PbA parasite dictate parasitemia bur-
den in Ifnar12/2 mice infection. In our experimental system (PbA-
GFP), type I IFN appears to be dominant during other stages of
ECM pathogenesis. Despite rapid and steep development of par-
asitemia throughout infection and parasite accumulation within
the brain tissue at levels comparable to susceptible C57BL/6 mice,
this was not enough to provoke a sufficient inflammatory response
for BBB compromise and mononuclear cell accumulation within
brain microvessels. It is worth mentioning that recombinant hu-
man IFN-a evoked a striking reduction in parasite burden and
protection from ECM in C57BL/6 mice, suggesting that the type I
IFN/IFNAR1 system has a role in parasite development (37).
Our data also point to type I IFN/IFNAR1 controlling disease
tolerance to malaria. Tolerance is a defense mechanism that does
not limit pathogen load (38), and this is in agreement with recent
studies that illustrate Ifnar12/2 mice providing a survival advan-
tage against Plasmodium infection (39). As a side note, the type I
IFN/IFNAR1–signaling system can also be regulated by heme
oxygenase-1, a stress-response enzyme associated with CM patho-
genesis in children, as we reported previously (25).
The development of a novel transfer protocol allowed us to focus
on cellular mechanisms involved in ECM protection conferred by
IFNAR1. These experiments uncovered that IFNAR1 is needed
unequivocally in primed splenic CD8+ T cells to abrogate ECM
resistance in Ifnar12/2 mice. The cytotoxic profile of CD8+
T cells in ECM induction has been shown using cell transfers;
perforin (40) and GrB (41) were identified as essential elements to
produce cytotoxicity and effector CD8+ T cell responses. Because
we saw no hindrance in the cytotoxic profile of splenic Ifnar12/2
CD8+ T cells upon infection (Fig. 7A–C), this suggests that
priming in the spleen is not impaired. However, because we ob-
served lower retention of activated CD8+ T cells in the brain of
Ifnar12/2 ECM-resistant mice, type I IFN could influence ECM
via its action in the brain. Type I IFN was shown to be critical in
maintaining CD8+ T cells at the site of their effector function (42);
therefore, this hints that unresponsive Ifnar12/2 CD8+ T cells may
have an impaired ability to accumulate within the brain tissue. We
question whether enabling the accumulation of IFNAR12 CD8+
T cells in the brain could generate enough power to trigger an
ECM response. We noted that Ifnar12/2 mice that received
primed CD8+ splenocytes accumulated relatively low numbers of
activated CD8+ T cells within the brain tissue, yet they developed
ECM (Fig. 7G–I). This supports the hypothesis that induction of
ECM in transferred mice was not due to CD8+ T cell accumulation
but rather was caused by their expression of IFNAR1, allowing
CD8+ T cells to become reactivated by type I IFN within the brain
and unleashing their cytotoxic effector capacity.
Evidence also showed that CD8+ T cells require constant Ag
presentation to remain at their effector site (43–45). Type I IFN
was shown to directly stimulate CD8+ T cell responses during Ag
cross-presentation (46). This suggests that resistance of Ifnar12/2
CD8+ T cells to inducing ECM could be due to their inability to
respond to type I IFN signals during Ag presentation within the
brain tissue. Moreover, the exact way in which CD8+ T cells are
presented in the brain is still unknown. We hypothesize that
IFNAR1 affects CD8+ T cell stimulation at different stages of
Plasmodium infection. We support the spleen as a primary site
of parasite Ag presentation and propose that a secondary site of
stimulation and presentation to CD8+ T cells occurs within the
brain tissue. In fact, transfer of Ifnar12/2 CD82 splenocytes caused
a slight increase in susceptibility to ECM, possibly reflecting the
effect of other immune cells, predominantly activated CD4+ T cells,
in promoting ECM development (47) by an IFNAR1-independent
mechanism.
Ifnar12/2 mice also have proved fundamental in uncovering the
therapeutic use of type I IFN in cancer (48), as well as in cases of
experimental autoimmune encephalomyelitis (17). However, in
support of our results, Ref. 45 reviews how type I IFN therapy has
led to the induction of autoimmune diseases. Our results induce
us to think that blocking IFNAR1 would be therapeutic for CM
protection; however, this would have to done with extreme pre-
cision because of the vast array of cells expressing IFNAR1, and,
more importantly, this would not directly mimic an IFNAR1 gene
polymorphism.
Our work collectively highlights the cohesive role of IFNAR1
during CM development, which is that it confers human CM
protection and it is implicated in CD8+ T cell pathology in mouse
ECM. These observations allow us to speculate that IFNAR1 may
operate in human CM through the stimulation of CD8+ T cells.
Together, these results identify responses of type I IFN through
IFNAR1 as vital components in CM pathogenesis.
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Figure S1. Transfer of non-exposed CD8
+





 mice that received total spleen cells (open squares) from C57BL/6 non-
exposed mice; transfer control is represented by infected Ifnar1
-/-
 mice that received no cell 
transfer (diamonds). (b) Ifnar1
-/-
 recipient mice that received sorted CD8
+
 spleen cells (open 
squares) or sorted CD8-depleted spleen cells (open circles) from C57BL/6 non-exposed mice; 
transfer control is represented by infected Ifnar1
-/-
 mice that received no cell transfer 
(diamonds). (c) Ifnar1
-/-
 mice that received sorted CD8
+
 spleen cells (open squares) or sorted 
CD8
-
 depleted spleen cells (open circles) from Ifnar1
-/-
 mice. (n = 3-6 mice per group, 
parasitemia; unpaired, two tailed t-test performed between CD8
+
 and CD8-depleted cell 
transfer recipient groups; *P  0.05, **P  0.01, survival curves; Log-rank Test). Each plot 
represents one of at least two independent experiments performed. Time window of C57BL/6 






 mice show no significant difference in CD4
+
 T cell numbers and 
activation profile compared to C57BL/6 mice upon infection. Total number of CD4
+
 T cells 
(a) and IFN-+ CD4+ T cells (b) in the spleen of non-infected (NI) and infected C57BL/6 and 
Ifnar1
-/-
 mice. Mice were infected 1  106 PbA, analyzed on day 5 PI. (n = 3-5 mice per group, 
non-parametric two tailed Mann Whitney test; *P  0.05, **P  0.01). Data is representative of 


























 T cells show cytotoxic ability like that of C57BL/6 mice. 
Mean fluorescence intensity (MFI) of GrB+ on CD8
+
 T cells (a) and IFN-+ on CD8+ T cells 
(b) in perfused brains of infected and non-infected C57BL/6 and Ifnar1
-/-
 mice, infected 1  106 
PbA, on day 6 PI when C57BL/6 displayed symptoms of ECM development. (n = 3-5 mice per 
group, unpaired, two tailed t-test; *P  0.05. Data is representative of three independent 
experiments performed 
 
 

